Dr. Ronghui Zheng 郑荣辉
Chief Physician
Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment and radiotherapy for head and neck tumors, with a focus on nasopharyngeal carcinoma.
Dr. Zheng is a Chief Physician and Doctor of Oncology at the Affiliated Cancer Hospital and Institute of Guangzhou Medical University. Roles include Deputy Director of the Radiotherapy Department and Teaching Director of the National Radiation Oncology Residency Training Base. Dr. Zheng has led or participated in over 10 projects, published more than 60 papers, and received over 10 awards.
Professional roles
- Chair, Guangdong Health Science Popularization Alliance
- Chair, Head and Neck Tumor Prevention and Treatment Branch, Guangdong Health Promotion Association
- Standing Committee Member, Chinese Medical Association
- Editorial Board Member, Journal of Practical Medicine
Name order: in Chinese the family name comes first (Zheng Ronghui). Papers usually list the name as Ronghui Zheng or Zheng R.
Selected publications
30 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Sci Rep, 2025 (senior author): Neck dose-limiting rings reduce head and neck lymphedema in early nasopharyngeal carcinoma patients undergoing IMRT: a dosimetric-clinical validation. PubMed 40189610
- Front Oncol, 2024 (senior author): Exploration of the value of concurrent chemotherapy for T2N1 nasopharyngeal carcinoma under intensity modulated radiotherapy mode. PubMed 39624632
- Clin Exp Immunol, 2023 (senior author): Therapeutic hyperthermia regulates complement C3 activation and suppresses tumor development through HSPA5/NFκB/CD55 pathway in nasopharyngeal carcinoma. PubMed 37249005
- J Cancer Res Clin Oncol, 2022 (senior author): Adjuvant chemotherapy following combined induction chemotherapy and concurrent chemoradiotherapy improves survival in N2-3-positive nasopharyngeal carcinoma patients. PubMed 34822015
- Asia Pac J Clin Oncol, 2022 (senior author): Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis. PubMed 33945215
- Int J Biol Markers, 2022 (senior author): Prognostic impact of pretreatment serum superoxide dismutase activity in patients with locoregionally advanced nasopharyngeal carcinoma. PubMed 35099330
- Oncol Res Treat, 2021 (senior author): Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma. PubMed 34601467
- J Cancer, 2021 (senior author): Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma. PubMed 33391399
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion